Patent intelligence · US
US 11168091
Quantification and preparation of pharmaceutical grade cantharidin
Quantification and preparation of pharmaceutical grade cantharidin
Patent details — US 11168091
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 9, 2021
- Expiration
- Nov 4, 2041
- Applicant
- Verrica Pharmaceuticals Inc.
- Claims
- 20
- CPC classes
- A61K, A61K31/365, A61P, A61P17/12
Quick answer
US 11168091 (Quantification and preparation of pharmaceutical grade cantharidin) is held by Verrica Pharmaceuticals Inc.. Status: granted. Granted Nov 9, 2021. Expires Nov 4, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Verrica Pharmaceuticals Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/365, A61P, A61P17/12, A61P31/20
More from Verrica Pharmaceuticals Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12290651
Devices and methods for the treatment of body surface disorders
granted -
US 12233042
Treatment of cutaneous disorders
granted -
US 12221452
Synthesis of cantharidin
granted -
US 11147790
Treatment of cutaneous disorders
granted -
US 11052064
Compositions, methods and systems for the treatment of cutaneous disorders
granted -
US 10745413
Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives
granted
Frequently asked questions
What is US patent 11168091?
US 11168091 (Quantification and preparation of pharmaceutical grade cantharidin) is held by Verrica Pharmaceuticals Inc.. Status: granted. Granted Nov 9, 2021. Expires Nov 4, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11168091?
Verrica Pharmaceuticals Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 11168091 expire?
Our index shows an expiration date of Nov 4, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.